FEATURED ARTICLES

• Critical Factors To Cell And Gene Therapy Forecasting

  Innovation in cell and gene therapies (CGTs) is leading to rapid growth in the space and transforming standards of care. Learn about the major considerations for developing CGT forecasts.

• Transforming Patient Engagement In Cell And Gene Therapy

  As cell and gene therapies expand, the patient voice will play an increasingly important role in treatment decisions. Learn how pharma can improve the patient experience and more.

• Lessons Learned From The Commercialization Of Gene Therapy Products

  Experts involved in launching a gene replacement therapy for spinal muscular atrophy share lessons learned during the commercialization journey along with thoughts for other cell and gene therapy manufacturers.

• Cancer Vaccines Represent The Next Frontier For Oncology And Personalized Medicine

  Strong results from a phase 2 trial represent a potential inflection point for oncology. Learn about the related implications, barriers to adoption and scale, recommendations for biopharmas, and more.

• Gene Therapy: Coming Of Age

  Explore some of the clinical and technical challenges gene therapies face along with a comparison of gene therapy and mAbs, including launched asset success, phase-transition failure rates, and more.

• The Impact Of Hospital-Developed CAR-T On The Cell Therapy Landscape

  Learn about how much hospital-developed CAR-Ts will impact the cell therapy landscape.

• CAR-T Reimbursement In The US: ZS Separates Myths From Reality

  Learn about the treatment landscape today from surveys collected at CAR-T treatment centers across the U.S. and  discussions with payers and treatment centers about CAR-T reimbursement realities.

• The CAR-T Experience: Lessons From The Quest For Speed And Performance

  Learn about the numerous opportunities to create differentiation and establish long-term leadership that our research uncovered and how CAR-T manufacturers can refine the processes and experience in clinical trials.

• Oncology Platforms And The Promise Of A Cure

  We discuss how a deepened understanding of cancer hallmarks and advances in science and engineering have set the stage for emerging therapeutic platforms.

• Evolving Trends To Watch For In The Cell And Gene Therapy Landscape

  We provide a landscape analysis of the industry with a future lens through which we highlight three key insights for C & GT.

• Transforming CGT Patient Engagement: A Strategic Imperative For Pharma

  Learn why strategically embedding a patient-first focus into CGT launch planning today could prove to be valuable investment in a CGT asset’s future.

• Promises And Risks Of Allogeneic Therapies

  Only a fraction of the population that could benefit from autologous cell therapies are receiving them. Read industry expert perspectives on the evolution of autologous and allogeneic cell therapies.

• Gene Therapies For All: Getting Treatments To Everyone In Need

  We explore the role gene therapy manufacturers play in addressing the challenge of slow adoption of these therapies to help pave the way for the future.

• How Do We Make Cell Therapy A Long-Term Sustainable Business?

  We explore barriers impacting the long-term viability of cell therapy manufacturing including complex delivery logistics and a long end-to-end journey, production capacity and scaling constraints, and manufacturing costs.

• Opportunities For Unlocking Future Growth With Cell Therapies

  As the market matures, we expect that the most impactful way to drive volume will not be through breadth alone, it also requires depth in optimizing site potential.